RB

Robert Blazej

Partner at Mission BioCapital, Director at MBC Biolabs

San Francisco, California

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Director

    2017

    MBC BioLabs helps life-science startups be fast and efficient. Our state-of-the-art life-science incubator rents space as small as a single lab bench and has a core facility with everything a startup needs to generate data on day-one.

  • Partner

    2017

    Mission Bay Capital uses capital and expertise to help entrepreneurial scientists change the world. MBC makes pivotal early-stage investments in life-science companies. Our focus is on helping startups efficiently resolve key technical risks. We accomplish this through our network of advisors, partners, and incubators.

  • Partner

    2017

    Mission BioCapital brings together two U.S.-based early-stage life science venture firms: BioInnovation Capital and Mission Bay Capital. For years, we have shared the same experienced team and the same vision. Now, we share the same name and a deep excitement about the future of life science innovation.

2013 - 2017

  • Manager

    2013 - 2017

    Novozymes is a global biotechnology company headquartered in Bagsværd outside of Copenhagen, Denmark. At Novozymes we challenge traditional industrial thinking and ask the world to Rethink Tomorrow. Together, we find biological answers for better lives in a growing world. We know that many of the answers which the world needs can be found in some of the smallest things in nature: inside the cells.

  • CEO & President

    2007 - 2013

    Allopartis Biotechnologies was founded in 2007 to develop optimized biocatalysts for industrial enzymes and synthetic biology. Located in San Francisco's Mission Bay Innovation Corridor, Allopartis packs a lot of science into a small space. Using single-molecules, Allopartis scientists search for the very best enzymes by performing billions of reactions in parallel. Allopartis was acquired by Novozymes in 2013.